Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Finished Goods: 2020-2024

Historic Finished Goods for Fortress Biotech (FBIO) over the last 5 years, with Dec 2024 value amounting to $11.4 million.

  • Fortress Biotech's Finished Goods rose 70.95% to $10.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $10.0 million, marking a year-over-year increase of 70.95%. This contributed to the annual value of $11.4 million for FY2024, which is 128.21% up from last year.
  • Latest data reveals that Fortress Biotech reported Finished Goods of $11.4 million as of FY2024, which was up 128.21% from $5.0 million recorded in FY2023.
  • Fortress Biotech's 5-year Finished Goods high stood at $11.4 million for FY2024, and its period low was $1.4 million during FY2020.
  • In the last 3 years, Fortress Biotech's Finished Goods had a median value of $7.7 million in 2022 and averaged $8.0 million.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 205.56% in 2021, then plummeted by 35.56% in 2023.
  • Yearly analysis of 5 years shows Fortress Biotech's Finished Goods stood at $1.4 million in 2020, then soared by 205.56% to $4.3 million in 2021, then soared by 80.40% to $7.7 million in 2022, then plummeted by 35.56% to $5.0 million in 2023, then spiked by 128.21% to $11.4 million in 2024.